These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8302771)

  • 1. Neuromelanin: a key to Parkinson's disease.
    Prota G; d'Ischia M
    Pigment Cell Res; 1993 Oct; 6(5):333-5. PubMed ID: 8302771
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuromelanin and nigrostriatal dopamine neuron degeneration.
    Jellinger K; Kienzl E; Rumpelmair G; Riederer P; Stachelberger H; Ben-Shachar D; Youdim MB
    J Neurochem; 1993 May; 60(5):1976-7. PubMed ID: 8473913
    [No Abstract]   [Full Text] [Related]  

  • 3. Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson's disease: a critical update.
    d'Ischia M; Prota G
    Pigment Cell Res; 1997 Dec; 10(6):370-6. PubMed ID: 9428003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the functional of neuromelanin.
    Smythies J
    Proc Biol Sci; 1996 Apr; 263(1369):487-9. PubMed ID: 8637929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
    Hirsch E; Graybiel AM; Agid YA
    Nature; 1988 Jul; 334(6180):345-8. PubMed ID: 2899295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective and toxic roles of dopamine in Parkinson's disease.
    Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
    J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromelanin and Parkinson's disease.
    Marsden CD
    J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromelanin-containing neurons are selectively vulnerable in parkinsonism.
    Langston JW
    Trends Pharmacol Sci; 1988 Oct; 9(10):347-8. PubMed ID: 3078067
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.
    Fedorow H; Tribl F; Halliday G; Gerlach M; Riederer P; Double KL
    Prog Neurobiol; 2005 Feb; 75(2):109-24. PubMed ID: 15784302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms underlying neuronal degeneration in Parkinson's disease: an experimental and theoretical treatise.
    Langston JW
    Mov Disord; 1989; 4 Suppl 1():S15-25. PubMed ID: 2542782
    [No Abstract]   [Full Text] [Related]  

  • 12. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease.
    Zecca L; Zucca FA; Albertini A; Rizzio E; Fariello RG
    Neurology; 2006 Oct; 67(7 Suppl 2):S8-11. PubMed ID: 17030740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease.
    Zucca FA; Segura-Aguilar J; Ferrari E; Muñoz P; Paris I; Sulzer D; Sarna T; Casella L; Zecca L
    Prog Neurobiol; 2017 Aug; 155():96-119. PubMed ID: 26455458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the origin and significance of neuromelanin.
    Graham DG
    Arch Pathol Lab Med; 1979 Jul; 103(7):359-62. PubMed ID: 582279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?
    Hirsch EC
    Ann Neurol; 1992; 32 Suppl():S88-93. PubMed ID: 1510386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromelanin and its possible protective and destructive properties.
    Lindquist NG; Larsson BS; Lydén-Sokolowski A
    Pigment Cell Res; 1987; 1(3):133-6. PubMed ID: 3334086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease.
    Bannon MJ; Goedert M; Williams B
    Biochem Pharmacol; 1984 Sep; 33(17):2697-8. PubMed ID: 6331828
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.